Please login to the form below

Early diagnosis underpins NHS cancer strategy

Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan

Introduction

Faster cancer diagnosis is a key ambition of the NHS Long-term Plan, which says that the proportion of cancers diagnosed at stages one and two should rise from around half now, to three quarters of cancer patients by 2028.

Raising greater awareness of the symptoms of cancer, lowering the threshold for referral by GPs, accelerating access to diagnosis and treatment and maximising the number of cancers identified through screening will be key to achieving this goal.

Cancer Alliances

The Long-term Plan gives the 19 Cancer Alliances - groups of cancer clinicians responsible for driving the development of cancer pathways at a local level – a central role.

The Cancer Alliances will advise Sustainability and Transformation Partnership (STP) and Integrated Care System (ICS) board members on cancer services and help to ensure that local cancer strategies are delivered.

Cancer Alliances have also been tasked with helping the NHS to achieve a new faster diagnosis standard. The standard, which will be introduced from 2020, is designed to ensure that most patients receive a definitive diagnosis or ruling out of cancer within 28 days of referral from a GP or from screening.

In addition, Cancer Alliances will also implement a new timed diagnostic pathway for specific cancers, building on the timed pathways already being introduced in lung, colorectal and prostate cancer.

Rapid Diagnostic Centres (RDCs)

Rapid Diagnostic Centres (RDCs), which were originally launched in pilot form in 2018, will underpin a radical overhaul of the way in which diagnostic services are delivered for patients with suspected cancer.

RDCs comprise multi-disciplinary teams which provide a single point of access to a diagnostic pathway for all patients with symptoms that could indicate cancer. These symptoms can be non-specific.

In addition to supporting the faster diagnosis standard, RDCs will complement work to improve screening programmes, augment the potential of artificial intelligence (AI) and genomic testing, and utilise Primary Care Networks (PCNs) to improve early diagnosis in their localities.

The success of RDCs will depend on corralling many disparate resources in the NHS – including GPs, who will form a big part of the service as they will refer patients with suspected symptoms to RDCs, supported by the local Cancer Alliance’s clinical network.

The 10 pilot RDCs are mostly clustered around the cancer vanguard areas of London and Manchester, with five in London, two in Manchester and one each in Leeds, Oxford, and Airedale, in the north west of England.

In 2019/20, all Cancer Alliances are expected to set up at least one RDC for patients with non-specific symptoms which could indicate cancer; as well as for a cohort of patients with site-specific symptoms who are currently served by an underperforming two week wait or 62-day pathway.

Primary Care Networks (PCNs)

As the NHS aims to move more care out of hospitals, PCNs are expected to play an important role in transforming cancer services. Indeed, the Long-term Plan states that PCNs will be required to help improve early diagnosis of patients in their neighbourhoods by 2023/24.  In line with this, early cancer diagnosis is one of seven new service specifications that PCNs must deliver and it is due to start by April 2020.

We expect to see multi-disciplinary teams working within PCNs to deliver cancer services and this could mean more cancer specialists, such as cancer nurses, working in the community, as well as other specialists, such as gastroenterologists.

Screening and diagnostic services will be increasingly provided in the community, where pilot schemes such as ‘MOTs for lungs’ and on-the-spot scans for patients at high risk of developing lung cancer, have shown the value of bringing these kinds of services closer to patients’ homes.

We can also expect to see some chemotherapy services, previously owned by NHS England, begin to become the responsibility of ICSs, particularly homecare services.

The Long-term Plan says that the NHS wants to use personalised and risk stratified screening and begin to test family members of cancer patients if they have an increased risk of the disease.  It is likely that PCNs will be tasked with quizzing patients about their family history in order to gather data that will support this proactive approach.

Gathering and analysing population health data around screening, including factors that deter patients from engaging with it, is invaluable for planning services. For example, most lung cancer diagnoses are made at stage four. However, research by Wilmington Healthcare shows that the chances of a patient being proactive about getting symptoms checked is affected by factors ranging from levels of deprivation in the local community to the quality of screening services.

Conclusion

Local or regional system empowerment is crucial for transforming NHS cancer services and so is integrated care; hence the work of Cancer Alliances and RDCs will be entwined within ICSs and PCNs.  This localised, targeted, population health approach will play an important role in delivering key aspirations within the Long-term Plan.

Ends

Paul Midgley is Director of NHS Insight; Sarah Shield is a Consultant and Oli Hudson is Content Director, all at Wilmington Healthcare. For information on Wilmington Healthcare, visit www.wilmingtonhealthcare.com

20th November 2019

Share

Tags

Company Details

Wilmington Healthcare

01268 495600

Contact Website

Address:
Beechwood House
2-3 Commercial Way
Christy Close
Southfields
Basildon
SS15 6EF
United Kingdom

Latest content on this profile

EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES
As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its part.
Wilmington Healthcare
UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS
Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected across all brand planning and engagement activity.
Wilmington Healthcare
Wilmington Healthcare appoints new director to lead cloud-based healthcare customer intelligence tool
Paul Rowe to lead intelligence tool that allows Industry to gain the complete picture of their changing NHS customer base and employ precision planning to access target customers and markets.
Wilmington Healthcare
LOOKING AHEAD: UNDERSTANDING THE NHS CUSTOMER’S PRIORITIES FOR 2022/23
The recently published operational planning guidance describes what the NHS needs to achieve this year. Wilmington Healthcare’s Oli Hudson explores some of its critical themes and what they mean for industry.
Wilmington Healthcare
NAVIGATING 2022: THE FIVE CRITICAL SHIFTS PHARMA NEEDS TO EMBRACE
With a stormy outlook predicted for health and care, Wilmington Healthcare’s Oli Hudson looks at the five critical shifts that pharma should focus on as it navigates its way through 2022.
Wilmington Healthcare
CHANGING FACES: UNDERSTANDING THE KEY CUSTOMER CONTACT POINTS WITHIN THE ICS LANDSCAPE
As well as creating new structures, the reforms underway within the NHS will see a considerable movement of people and power across the new Integrated Care Systems. Wilmington Healthcare’s Victoria Paxman looks at how the landscape of key influencers and decision-makers will change as a result.
Wilmington Healthcare